Preview

Сахарный диабет

Расширенный поиск

Роль эндотелиальных прогениторных клеток в развитии осложнений сахарного диабета

https://doi.org/10.14341/DM2015124-32

Полный текст:

Аннотация

У больных сахарным диабетом (СД) риск развития сердечно-сосудистых заболеваний (ССЗ) в 2?4 раза выше, чем у больных без нарушения углеводного обмена. При СД хроническая гипергликемия запускает ряд патофизиологических механизмов, приводящих к повреждению эндотелия. В настоящее время считается, что в процессе восстановления эндотелия принимают участие циркулирующие клетки-предшественницы, выделяющиеся из костного мозга (КМ). Данные клетки, так называемые эндотелиальные прогениторные клетки (ЭПК), участвуют в поддержании функции эндотелия и способствуют его восстановлению после повреждения, а также образованию новых кровеносных сосудов. Многочисленные литературные данные показывают, что при СД наблюдается снижение количества и нарушение функции ЭПК. Кроме того, у больных СД нарушается адекватная реакция со стороны КМ в ответ на стимулирующие факторы. В данном обзоре рассмотрена роль ЭПК в развитии и прогрессировании микро- и макрососудистых осложнений СД.

Об авторах

Марина Сергеевна Мичурова
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
Россия

Аспирант 


Конфликт интересов: Авторы декларируют отсутствие двойственности (конфликта) интересов, связанных с данной рукописью.


Виктор Юрьевич Калашников
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
Россия
доктор медицинских наук, заведующий отделом неотложной и интервенционной кардиологии
Конфликт интересов:

Авторы декларируют отсутствие двойственности (конфликта) интересов, связанных с данной рукописью



Ольга Михайловна Смирнова
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
Россия
доктор медицинских наук, профессор, главный научный сотрудник отделения программного обучения и лечения
Конфликт интересов:

Авторы декларируют отсутствие двойственности (конфликта) интересов, связанных с данной рукописью



Ирина Владимировна Кононенко
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
Россия
кандидат медицинских наук, ведущий научный сотрудник отделения программного обучения и лечения
Конфликт интересов: Авторы декларируют отсутствие двойственности (конфликта) интересов, связанных с данной рукописью


Ольга Николаевна Иванова
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
Россия
кандидат биологических наук, заведующая лабораторией генетики и клинической иммунологии
Конфликт интересов: Авторы декларируют отсутствие двойственности (конфликта) интересов, связанных с данной рукописью.


Список литературы

1. Avogaro A, de Kreutzenberg SV, Fadini G. Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes research and clinical practice. 2008;82 Suppl 2:S94–S101. doi: 10.1016/j.diabres.2008.09.021

2. Brownlee M. The Pathobiology of Diabetic Complications: A Unifying Mechanism. Diabetes. 2005;54(6):1615–1625. doi: 10.2337/diabetes.54.6.1615.

3. Asahara T. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. Science. 1997;275(5302):964–966. doi: 10.1126/science.275.5302.964.

4. Ii M, Takenaka H, Asai J, et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circulation research. 2006;98(5):697–704. doi: 10.1161/01.RES.0000209948.50943.ea

5. Hazarika S, Dokun AO, Li Y, et al. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circulation research. 2007;101(9):948–956. doi: 10.1161/CIRCRESAHA.107.160630

6. Fadini GP, Sartore S, Agostini C, Avogaro A. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes care. 2007;30(5):1305–1313. doi: 10.2337/dc06-2305

7. Authors/Task Force M, Ryden L, Grant PJ, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European heart journal. 2013;34(39):3035–3087. doi: 10.1093/eurheartj/eht108

8. Khan SS, Solomon MA, McCoy JP. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry Part B: Clinical Cytometry. 2005;64B(1):1–8. doi: 10.1002/cyto.b.20040.

9. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000;95(3):952–958.

10. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998;92(2):362–367.

11. Gehling UM, Ergun S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000;95(10):3106–3112.

12. Masuda H, Alev C, Akimaru H, et al. Methodological development of a clonogenic assay to determine endothelial progenitor cell potential. Circulation research. 2011;109(1):20–37. doi: 10.1161/CIRCRESAHA.110.231837

13. Case J, Mead LE, Bessler WK, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp. Hematol. 2007;35(7):1109–1118. doi: 10.1016/j.exphem.2007.04.002.

14. Bethel K, Luttgen MS, Damani S, et al. Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction. Physical biology. 2014;11(1):016002. doi: 10.1088/1478-3975/11/1/016002

15. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: isolation and characterization. Trends in cardiovascular medicine. 2003;13(5):201–206. doi: 10.1016/S1050-1738(03)00077-X

16. Fadini GP, Losordo D, Dimmeler S. Critical re-evaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circulation research. 2012;110(4):624–637. doi: 10.1161/CIRCRESAHA.111.243386

17. Caiado F, Dias S. Endothelial progenitor cells and integrins: adhesive needs. Fibrogenesis & tissue repair. 2012;5:4. doi: 10.1186/1755-1536-5-4

18. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circulation research. 2004;95(4):343–353. doi: 10.1161/01.RES.0000137877.89448.78

19. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858–864. doi: 10.1038/nm1075

20. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109(5):625–637. doi: 10.1016/S0092-8674(02)00754-7

21. Krankel N, Adams V, Linke A, et al. Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arteriosclerosis, thrombosis, and vascular biology. 2005;25(4):698–703. doi: 10.1161/01.ATV.0000156401.04325.8f

22. Yiu KH, Tse HF. Specific role of impaired glucose metabolism and diabetes mellitus in endothelial progenitor cell characteristics and function. Arteriosclerosis, thrombosis, and vascular biology. 2014;34(6):1136–1143. doi: 10.1161/ATVBAHA.114.302192

23. Fadini GP. An underlying principle for the study of circulating progenitor cells in diabetes and its complications. Diabetologia. 2008;51(7):1091–1094. doi: 10.1007/s00125-008-1021-0

24. Fadini GP, Pucci L, Vanacore R, et al. Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia. 2007;50(10):2156–2163. doi: 10.1007/s00125-007-0732-y

25. Tepper OM, Galiano RD, Capla JM, et al. Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures. Circulation. 2002;106(22):2781–2786. doi: 10.1161/01.cir.0000039526.42991.93

26. Loomans CJ, de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004;53(1):195–199. doi: 10.2337/diabetes.53.1.195

27. Кочегура Т.Н., Акопян Ж.А., Шаронов Г.В., и др. Влияние сопутствующего сахарного диабета 2 типа на количество циркулирующих прогениторных клеток у больных с ишемической кардиомиопатией. // Сахарный диабет. – 2011. – №3 – С. 36–43. [Kochegura TN, Akopyan ZA, Sharonov GV, et al. The influence of concomitant type 2 diabetes mellitus on the number of circulating progenitor cells in patients with ischemic cardiomyopathy. Diabetes mellitus. 2011;14(3):36–43.] doi: 10.14341/2072-0351-6222

28. Dessapt C, Karalliedde J, Hernandez-Fuentes M, et al. Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes care. 2010;33(4):875–877. doi: 10.2337/dc09-1468.

29. Brunner S, Schernthaner GH, Satler M, et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data. Investigative ophthalmology & visual science. 2009;50(1):392–398. doi: 10.1167/iovs.08-1748

30. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. Journal of the American College of Cardiology. 2005;45(9):1449–1457. doi: 10.1016/j.jacc.2004.11.067

31. Choi JH, Kim KL, Huh W, et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arteriosclerosis, thrombosis, and vascular biology. 2004;24(7):1246–1252. doi: 10.1161/01.ATV.0000133488.56221.4a

32. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. Journal of the American College of Cardiology. 2005;46(9):1693–1701. doi: 10.1016/j.jacc.2005.04.066

33. Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103(3):921–926. doi: 10.1182/blood-2003-04-1284

34. Herbrig K, Gebler K, Oelschlaegel U, et al. Kidney transplantation substantially improves endothelial progenitor cell dysfunction in patients with end-stage renal disease. American journal of transplantation. 2006;6(12):2922–2928. doi: 10.1111/j.1600-6143.2006.01555.x

35. Makino H, Okada S, Nagumo A, et al. Decreased circulating CD34+ cells are associated with progression of diabetic nephropathy. Diabetic medicine. 2009;26(2):171–173. doi: 10.1111/j.1464-5491.2008.02638.x

36. Butler JM, Guthrie SM, Koc M, et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. Journal of Clinical Investigation. 2005;115(1):86–93. doi: 10.1172/JCI200522869

37. Fadini GP, Sartore S, Baesso I, et al. Endothelial progenitor cells and the diabetic paradox. Diabetes care. 2006;29(3):714–716. doi: 10.2337/diacare.29.03.06.dc05-1834

38. Asnaghi V, Lattanzio R, Mazzolari G, et al. Increased clonogenic potential of circulating endothelial progenitor cells in patients with type 1 diabetes and proliferative retinopathy. Diabetologia. 2006;49(5):1109–1111. doi: 10.1007/s00125-006-0180-0

39. Tan K, Lessieur E, Cutler A, et al. Impaired function of circulating CD34(+) CD45(-) cells in patients with proliferative diabetic retinopathy. Experimental eye research. 2010;91(2):229–237. doi: 10.1016/j.exer.2010.05.012

40. Fadini GP. Is bone marrow another target of diabetic complications? European journal of clinical investigation. 2011;41(4):457–463. doi: 10.1111/j.1365-2362.2010.02417.x

41. Ferraro F, Lymperi S, Mendez-Ferrer S, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Science translational medicine. 2011;3(104):104ra101. doi: 10.1126/scitranslmed.3002191

42. Fadini GP, Albiero M, Vigili de Kreutzenberg S, et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes care. 2013;36(4):943–949. doi: 10.2337/dc12-1084

43. Fadini GP, Ferraro F, Quaini F, et al. Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. Stem cells translational medicine. 2014;3(8):949–957. doi: 10.5966/sctm.2014-0052

44. Fadini GP. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia. 2014;57(1):4–15. doi: 10.1007/s00125-013-3087-6

45. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. The New England journal of medicine. 2003;348(7):593–600. doi: 10.1056/NEJMoa022287

46. Vasa M, Fichtlscherer S, Aicher A, et al. Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease. Circulation research. 2001;89(1):e1–e7. doi: 10.1161/hh1301.093953

47. Sibal L, Aldibbiat A, Agarwal SC, et al. Circulating endothelial progenitor cells, endothelial function, carotid intima–media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia. 2009;52(8):1464–1473. doi: 10.1007/s00125-009-1401-0

48. Fadini GP, Coracina A, Baesso I, et al. Peripheral Blood CD34+KDR+ Endothelial Progenitor Cells Are Determinants of Subclinical Atherosclerosis in a Middle-Aged General Population. Stroke. 2006;37(9):2277–2282. doi: 10.1161/01.str.0000236064.19293.79

49. Kunz GA, Liang G, Cuculi F, et al. Circulating endothelial progenitor cells predict coronary artery disease severity. American heart journal. 2006;152(1):190–195. doi: 10.1016/j.ahj.2006.02.001

50. Fadini GP, Sartore S, Albiero M, et al. Number and Function of Endothelial Progenitor Cells as a Marker of Severity for Diabetic Vasculopathy. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(9):2140–2146. doi: 10.1161/01.atv.0000237750.44469.88

51. Massa M, Rosti V, Ferrario M, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2004;105(1):199–206. DOI:10.1182/blood-2004-05-1831

52. Marti-Fabregas J, Crespo J, Delgado-Mederos R, et al. Endothelial progenitor cells in acute ischemic stroke. Brain and behavior. 2013;3(6):649–655. doi: 10.1002/brb3.175

53. Руда М.М., Арефьева Т.И., Соколова А.В., и др. Циркулирующие предшественники эндотелиальных клеток при нарушенном углеводном обмене у больных ишемической болезнью сердца. // Сахарный диабет. – 2010. – №1. – С. 13–20. [Ruda MM, Aref'eva TI, Sokolova AV, Shestakova MV, Karpov YA, Parfenova EV. Circulating precursors of endothelial cells in patients with CHD and disturbed carbohydrate metabolism. Diabetes mellitus. 2010;13(1):13–20]. doi: 10.14341/2072-0351-6011

54. Ling L, Shen Y, Wang K, et al. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization. PloS one. 2012;7(11):e50739. doi: 10.1371/journal.pone.0050739

55. Antonio N, Fernandes R, Soares A, et al. Reduced levels of circulating endothelial progenitor cells in acute myocardial infarction patients with diabetes or pre-diabetes: accompanying the glycemic continuum. Cardiovascular diabetology. 2014;13:101. doi: 10.1186/1475-2840-13-101

56. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. The New England journal of medicine. 2005;353(10):999–1007. doi: 10.1056/NEJMoa043814

57. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111(22):2981–2987. doi: 10.1161/CIRCULATIONAHA.104.504340

58. Schwartzenberg S, Afek A, Charach G, et al. Comparative analysis of the predictive power of different endothelial progenitor cell phenotypes on cardiovascular outcome. World journal of cardiology. 2010;2(9):299–304. doi: 10.4330/wjc.v2.i9.299

59. Fadini GP, Maruyama S, Ozaki T, et al. Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PloS one. 2010;5(7):e11488. doi: 10.1371/journal.pone.0011488

60. Inoue T, Croce K, Morooka T, et al. Vascular Inflammation and Repair: Implications for Reendothelialization, Restenosis, and Stent Thrombosis. JACC Cardiovascular Interventions. 2011;4(10):1057–1066. doi: 10.1016/j.jcin.2011.05.025

61. Bonello L, Harhouri K, Baumstarck K, et al. Mobilization of CD34+KDR+ endothelial progenitor cells predicts target lesion revascularization. Journal of Thrombosis and Haemostasis. 2012;10(9):1906–1913. doi: 10.1111/j.1538-7836.2012.04854.x

62. Pelliccia F, Cianfrocca C, Rosano G, et al. Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: a prospective study. JACC Cardiovascular Interventions.. 2010;3(1):78–86. doi: 10.1016/j.jcin.2009.10.020

63. Pelliccia F, Pasceri V, Rosano G, et al. Endothelial progenitor cells predict long-term prognosis in patients with stable angina treated with percutaneous coronary intervention: five-year follow-up of the PROCREATION study. Circulation journal. 2013;77(7):1728–1735. doi: 10.1253/circj.CJ-12-1608

64. Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European journal of cardio-thoracic surgery. 2014;46(4):517-592. doi: 10.1093/ejcts/ezu366

65. Zhao CT, Wang M, Siu CW, et al. Myocardial dysfunction in patients with type 2 diabetes mellitus: role of endothelial progenitor cells and oxidative stress. Cardiovascular diabetology. 2012;11:147. doi: 10.1186/1475-2840-11-147


Дополнительные файлы

Для цитирования:


Мичурова М.С., Калашников В.Ю., Смирнова О.М., Кононенко И.В., Иванова О.Н. Роль эндотелиальных прогениторных клеток в развитии осложнений сахарного диабета. Сахарный диабет. 2015;18(1):24-32. https://doi.org/10.14341/DM2015124-32

For citation:


Michurova M.C., Kalashnikov V.Yu., Smirnova O.M., Kononenko I.V., Ivanova O.N. Endothelial progenitor cells in diabetes complications. Diabetes mellitus. 2015;18(1):24-32. (In Russ.) https://doi.org/10.14341/DM2015124-32

Просмотров: 56


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2072-0351 (Print)
ISSN 2072-0378 (Online)